Building 4
Room 302, 3rd Floor No.590 Ruiqing Road East Zhangjiang Hi-Tech Park, Pudong New Area
Shanghai
China
86 21 6879 8511
https://www.bio-heart.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 32
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Li Wang | Executive Chairman of the Board, CEO & GM | 778.06k | N/D | 1968 |
Mr. Yunqing Wang | CFO, Joint Company Secretary & Executive Director | 1.29M | N/D | 1985 |
Ms. Peili Wang | Financial Manager & Executive Director | 829.71k | N/D | 1984 |
Dr. Bradley Stewart Hubbard D.V.M., DVM | Chief Medical Officer | N/D | N/D | 1959 |
Ms. Siu Ying Kwok | Joint Company Secretary | N/D | N/D | 1985 |
Mr. Tao Cai | Chairperson of the Board of Supervisors & Head of Technology of BRS | 178.03k | N/D | 1987 |
Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
La calificación ISS Governance QuickScore de Shanghai Bio-heart Biological Technology Co., Ltd. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.